Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.78 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 5/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CASR | P41180 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14696198 | 1.00 | AR (0.78) | ARHTTHIF1AKMT2AADRB3 | |
| SCHEMBL14695595 | 0.89 | AR (0.61) | ARHTTHIF1AKMT2AADRB3 | |
| SCHEMBL14695594 | 0.89 | AR (0.61) | ARHTTHIF1AKMT2AADRB3 | |
| SCHEMBL12267194 | 0.88 | AR (1.00) | ARHTTHIF1AKMT2AMEN1 | |
| SCHEMBL12989741 | 0.88 | AR (1.00) | ARHTTHIF1AKMT2AMEN1 | |
| SCHEMBL14730835 | 0.88 | AR (1.00) | ARHTTHIF1AKMT2AMEN1 | |
| SCHEMBL14730837 | 0.88 | AR (1.00) | ARHTTHIF1AKMT2AMEN1 | |
| SCHEMBL13736034 | 0.88 | AR (1.00) | ARHTTHIF1AKMT2AMEN1 | |
| SCHEMBL14730839 | 0.88 | AR (1.00) | ARHTTHIF1AKMT2AMEN1 | |
| SCHEMBL15257224 | 0.88 | AR (1.00) | ARHTTHIF1AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170121261-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNITED STATES GOVERNMENT | 2017-05-04 | — | — | US | disclosed |
| US-20170121261-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | THE UNITED STATES GOVERNMENT | 2017-05-04 | — | — | US | disclosed |
| EP-2744773-B1 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE | BRITISH COLUMBIA CANCER AGENCY (CA) | 2016-11-02 | — | — | EP | disclosed |
| US-20130045204-A1 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121261-A1 | DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE | UGCG, PTGFR, KLK3 | AR 206/4885HTT 4813/4885HIF1A 530/4885 |
| US-20130045204-A1 | FLUORINATED BISPHENOL ETHER COMPOUNDS AND METHODS FOR THEIR USE | AR, ESRRA, ESR1 | AR 1/4885HTT 3985/4885HIF1A 3869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.